Recruiting
Phase 2

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

Sponsor:

Canadian Myeloma Research Group

Code:

NCT05272826

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 65+

Healthy Volunteers: Not accepted

Interventions

Iberdomide

Bortezomib

Dexamethasone

Isatuximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information